The Efficacy of Double Filtration Plasmapheresis in Severe Fever With Thrombocytopenia Syndrome: A Multicenter Retrospective Study.

IF 1.2

Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy Pub Date : 2026-09-17 DOI:10.1002/1744-9987.70222

Shuqin Sun, Hongsen Tian, Xia Li, Shuo Yang

{"title":"The Efficacy of Double Filtration Plasmapheresis in Severe Fever With Thrombocytopenia Syndrome: A Multicenter Retrospective Study.","authors":"Shuqin Sun, Hongsen Tian, Xia Li, Shuo Yang","doi":"10.1002/1744-9987.70222","DOIUrl":null,"url":null,"abstract":"Introduction: Double filtration plasmapheresis (DFPP) effectively removes toxins and inflammatory cytokines and is widely used for critical illnesses. However, evidence supporting DFPP use in severe fever with thrombocytopenia syndrome (SFTS) is scarce.Methods: We enrolled 144 severe SFTS patients matched 1:1 into DFPP and control groups (72 patients per group). Baseline characteristics were balanced between groups. Oxygenation, hemodynamics, inflammatory cytokines, and clinical endpoints (ICU stay, ventilation duration, complications, ICU, and 30-day mortality) were compared.Results: The two matched groups showed comparable baseline characteristics. DFPP improved oxygenation and hemodynamic indices, suppressed inflammatory cytokines, shortened ICU stay (13 (9-18) vs16 (12-23) days, p = 0.001), mechanical ventilation duration (8 (6-11) vs. 10 (7-13) days, p = 0.002), and lowered ICU mortality (9 (12.50) vs. 20 (27.78), p = 0.018) and 30-day mortality (p = 0.01).Conclusions: DFPP alleviates clinical manifestations and improves prognosis in patients with severe SFTS.","PeriodicalId":94253,"journal":{"name":"Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy","volume":" ","pages":""},"PeriodicalIF":1.2000,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/1744-9987.70222","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Double filtration plasmapheresis (DFPP) effectively removes toxins and inflammatory cytokines and is widely used for critical illnesses. However, evidence supporting DFPP use in severe fever with thrombocytopenia syndrome (SFTS) is scarce.

Methods: We enrolled 144 severe SFTS patients matched 1:1 into DFPP and control groups (72 patients per group). Baseline characteristics were balanced between groups. Oxygenation, hemodynamics, inflammatory cytokines, and clinical endpoints (ICU stay, ventilation duration, complications, ICU, and 30-day mortality) were compared.

Results: The two matched groups showed comparable baseline characteristics. DFPP improved oxygenation and hemodynamic indices, suppressed inflammatory cytokines, shortened ICU stay (13 (9-18) vs16 (12-23) days, p = 0.001), mechanical ventilation duration (8 (6-11) vs. 10 (7-13) days, p = 0.002), and lowered ICU mortality (9 (12.50) vs. 20 (27.78), p = 0.018) and 30-day mortality (p = 0.01).

Conclusions: DFPP alleviates clinical manifestations and improves prognosis in patients with severe SFTS.

查看原文本刊更多论文

双滤过血浆置换治疗发热伴血小板减少综合征疗效：一项多中心回顾性研究。

双过滤血浆置换术（DFPP）能有效去除毒素和炎症细胞因子，广泛应用于危重疾病。然而，支持DFPP用于发热伴血小板减少综合征（SFTS）的证据很少。方法：144例重度SFTS患者按1:1比例分为DFPP组和对照组（每组72例）。各组间基线特征平衡。比较氧合、血流动力学、炎症因子和临床终点（ICU住院时间、通气时间、并发症、ICU和30天死亡率）。结果：两个匹配组显示出可比的基线特征。DFPP改善氧合和血流动力学指标，抑制炎症因子，缩短ICU住院时间（13（9-18）天和16（12-23）天，p = 0.001），缩短机械通气时间（8（6-11）天和10（7-13）天，p = 0.002），降低ICU死亡率（9（12.50）天和20（27.78）天，p = 0.018），降低30天死亡率（p = 0.01）。结论：DFPP可缓解重度SFTS患者的临床表现，改善预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy

自引率

0.00%

发文量